免疫系统辐射剂量对接受立体定向体部放疗的早期非小细胞肺癌疾病进展和生存的影响
该回顾性研究纳入211例病理确诊的早期非小细胞肺癌患者(2007–2020年接受SBRT),计算免疫细胞估计辐射剂量(EDRIC),中位随访48个月。多因素分析显示较高EDRIC与更差CSS(HR=1.468,P=0.009)和DMFS(HR=1.491,P=0.016)显著相关,并在119例独立验证队列中验证。EDRIC受GTV和肿瘤位置影响,作者认为需进一步研究在保证肿瘤覆盖前提下降低EDRIC的可行性。
要点
- 较高EDRIC与更差CSS(HR=1.468,P=0.009)和DMFS(HR=1.491,P=0.016)显著相关。
- GTV与EDRIC呈正相关(r=0.707,P=0.000)。
- EDRIC是ES-NSCLC的CSS和DMFS独立预测因子,受GTV和肿瘤位置影响。
核心结论
- EDRIC是早期非小细胞肺癌CSS和DMFS的独立预测因子,且受GTV和肿瘤位置影响。
- EDRIC可量化且潜在可调控,但作者认为需进一步研究在放疗中实现较低EDRIC同时保持足够肿瘤覆盖的可行性。
研究设计与样本
- 回顾性分析2007–2020年接受SBRT的211例病理确诊早期非小细胞肺癌患者,中位随访48个月。
- EDRIC基于Jin等开发并由Ladbury等改进的模型计算。
- 采用Kaplan-Meier法和Cox比例风险回归估计CSS、PFS、LPFS和DMFS,Pearson相关评估变量间相关性。
- 在119例早期非小细胞肺癌患者的独立队列中验证 findings。
主要发现
- 训练队列211例,中位EDRIC为2.178 Gy(范围:0.426–6.015)。
- GTV与EDRIC呈正相关(r=0.707,P=0.000)。
- 多因素分析中较高EDRIC与更差CSS显著相关(HR=1.468,P=0.009)。
- 多因素分析中较高EDRIC与更差DMFS显著相关(HR=1.491,P=0.016)。
- 按EDRIC四分位分组,CSS在第1与第4四分位间(P=0.000)及第1与第3四分位间(P=0.004)差异显著;DMFS在第1与第4四分位间(P=0.000)、第1与第3四分位间(P=0.000)及第1与第2四分位间(P=0.008)差异显著。
关键数值与推荐
- 中位EDRIC为2.178 Gy(范围:0.426–6.015)。
- 较高EDRIC与更差CSS相关:HR=1.468,P=0.009。
- 较高EDRIC与更差DMFS相关:HR=1.491,P=0.016。
- GTV与EDRIC正相关:r=0.707,P=0.000。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性分析。
- 作者认为需进一步研究在放疗中实现较低EDRIC同时保持足够肿瘤覆盖的可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although the effects of estimated dose of radiation to immune cells (EDRIC) in stage III NSCLC, LA-NSCLC, LS-SCLC and esophageal cancer on clinical outcomes have been studied, its impact in early-stage non-small cell lung cancer (ES-NSCLC) is unknown. In this study, we evaluated the role of EDRIC and identified the factors influencing EDRIC in this population. METHODS AND MATERIALS: We retrospectively analyzed 211 pathologically confirmed ES-NSCLC patients who were treated with SBRT between 2007 and 2020. EDRIC was calculated based on the model developed by Jin et al. and improved by Ladbury et al. Kaplan-Meier method and Cox proportional hazards regression were adopted to estimate CSS, PFS, LPFS, and DMFS. Pearson correlation was used to assess the correlation between variables. We further validated our findings in an independent cohort of 119 patients with ES-NSCLC. RESULTS: A total of 211 patients were included with median follow-up of 48 months in the training cohort. The median EDRIC was 2.178 Gy (range: 0.426-6.015). GTV showed a positive correlation with EDRIC (r = 0.707, P = 0.000). In multivariate analysis, higher EDRIC was significantly associated with worse CSS (HR = 1.468, P = 0.009) and DMFS (HR = 1.491, P = 0.016). Considering each EDRIC quartile, there was a significant difference in CSS between 1st and 4th and 1st and 3rd quartile (P = 0.000, P = 0.004, respectively); and DMFS between 1st and 4th,1st and 3rd, and 1st and 2nd quartile (P = 0.000, P = 0.000, P = 0.008, respectively). In the subgroup and validation cohort, EDRIC was also the important prognostic predictor of CSS and DMFS using multivariate analysis. CONCLUSION: EDRIC was an independent predictor of CSS and DMFS in ES-NSCLC, and it was affected by GTV and tumor location. Though EDRIC is a critical determinant of treatment outcomes, it is quantifiable and potentially modifiable. Additional researches exploring the feasibility of achieving lower EDRIC while maintaining adequate tumor coverage during radiotherapy are warranted.
引用
- Wang X, Bai H, Gao M, et al. Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Radiother Oncol. 2023. PMID: 37437605. doi:10.1016/j.radonc.2023.109804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。